公开(公告)号：US20040225020A1

公开(公告)日：2004-11-11

申请号：US10848069

申请日：2004-05-19

Applicant: Sepracor Inc.

Inventor： John R. McCullough ,  Paul D. Rubin

IPC: A61K031/137

CPC classification number: A61K31/137 ,  A61K31/135

Abstract: Methods and compositions are disclosed utilizing the optically pure (null)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

Abstract translation: 公开了使用安非他酮的光学纯的（ - ） - 异构体来帮助戒烟，治疗吸烟和尼古丁成瘾以及治疗疼痛的方法和组合物，包括但不限于慢性疼痛，神经性疼痛和反射性交感神经营养不良 ，以及其他疾病如发作性睡病，慢性疲劳综合征，纤维肌痛，季节性情感障碍和经前期综合征，同时避免与外消旋安非他酮相关的不良影响。

公开(公告)号：US20010020031A1

公开(公告)日：2001-09-06

申请号：US09809165

申请日：2001-03-16

Applicant: Sepracor Inc.

Inventor： John R. McCullough ,  Thomas P. Jerussi

IPC: A61K031/445

CPC classification number: A61K31/495 ,  A61K31/4468 ,  A61K2300/00

Abstract: Compositons employing and methods utilizing the optically pure (null) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (null) norcisapride, has also been found to be a potent antiemetic agent. Finally, the (null) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions.

Abstract translation: 公开了使用诺西西滨的旋光纯（+）异构体的复合物和方法。 令人惊讶地发现，该化合物是用于治疗中枢神经系统疾病的有效药物。 化合物（+）诺西沙必利还被发现是一种有效的止吐剂。 最后，诺西沙必利的（+）异构体也避免了某些不良副作用和某些不良药物相互作用。

公开(公告)号：US20040044039A1

公开(公告)日：2004-03-04

申请号：US10653072

申请日：2003-09-03

Applicant: Sepracor Inc.

Inventor： John R. McCullough ,  Thomas P. Jerussi

IPC: A61K031/445

CPC classification number: A61K31/495 ,  A61K31/4468 ,  A61K2300/00

Abstract: Compositons employing and methods utilizing the optically pure (null) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (null) norcisapride, has also been found to be a potent antiemetic agent. Finally, the (null) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions.

Abstract translation: 公开了使用诺西西滨的旋光纯（+）异构体的复合物和方法。 令人惊讶地发现，该化合物是用于治疗中枢神经系统疾病的有效药物。 化合物（+）诺西沙必利还被发现是一种有效的止吐剂。 最后，诺西沙必利的（+）异构体也避免了某些不良副作用和某些不良药物相互作用。

公开(公告)号：US20030096873A1

公开(公告)日：2003-05-22

申请号：US10277905

申请日：2002-10-23

Applicant: Sepracor Inc.

Inventor： John R. McCullough ,  Paul D. Rubin

IPC: A61K031/137

CPC classification number: A61K31/137 ,  A61K9/2018 ,  A61K9/2059 ,  A61K31/135

Abstract: Methods and compositions are disclosed utilizing the optically pure (null)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

公开(公告)号：US20020183241A1

公开(公告)日：2002-12-05

申请号：US10146415

申请日：2002-05-16

Applicant: Sepracor Inc.

Inventor： John R. McCullough

IPC: A61K031/00

CPC classification number: A61K31/4545

Abstract: Methods for treating urinary incontinence, vertigo and motion sickness comprising administering a therapeutically effective amount of descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof.

Abstract translation: 用于治疗尿失禁，眩晕和晕车的方法，包括给予治疗有效量的去甲氧基乙酰基吗啡胺或其药学上可接受的盐。

公开(公告)号：US20010011103A1

公开(公告)日：2001-08-02

申请号：US09803956

申请日：2001-03-13

Applicant: Sepracor Inc.

Inventor： John R. McCullough ,  Paul D. Rubin

IPC: A61K031/135

CPC classification number: A61K31/137 ,  A61K9/2018 ,  A61K9/2059 ,  A61K31/135

Abstract: Methods and compositions are disclosed utilizing the optically pure (null)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

Abstract translation: 公开利用安非他酮的光学纯的（+）异构体来帮助戒烟，治疗吸烟和尼古丁成瘾以及治疗疼痛的方法和组合物，包括但不限于慢性疼痛，神经性疼痛和反射性交感神经营养不良 ，以及其他疾病如发作性睡病，慢性疲劳综合征，纤维肌痛，季节性情感障碍和经前期综合征，同时避免与外消旋安非他酮相关的不良影响。